Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Ipilimumab
Related studies linked through entity extraction aliases.
Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- EARLY_PHASE1
Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)
- Status
- TERMINATED
- Phase
- PHASE2
An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition
- Status
- COMPLETED
- Phase
- N/A
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
- Status
- TERMINATED
- Phase
- PHASE3
An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed
- Status
- TERMINATED
- Phase
- PHASE1
PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
- Status
- COMPLETED
- Phase
- PHASE2
Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma
- Status
- TERMINATED
- Phase
- PHASE1
Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
- Status
- TERMINATED
- Phase
- PHASE2
A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
- Status
- TERMINATED
- Phase
- PHASE1
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
- Status
- TERMINATED
- Phase
- PHASE2
A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Phase IIb Study Evaluating Immunogenic Chemotherapy Combined with Ipilimumab and Nivolumab in Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)
- Status
- COMPLETED
- Phase
- PHASE1